/CYBN
CYBN Stock - Cybin Inc.
Healthcare|BiotechnologyAMEX
$7.18+6.06%
+$0.41 (+6.06%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $7.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CYBN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.11 – $7.25
TARGET (TP)$8.26
STOP LOSS$6.61
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.09
52W High$10.73
52W Low$4.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $864,000 |
| Gross Profit | N/A | $-424,000 | $-251,000 | $-168,000 | $200,000 |
| Gross Margin | N/A | N/A | N/A | N/A | 23.1% |
| Operating Income | $-143,147,000 | $-78,836,000 | $-51,518,000 | $-63,838,000 | $-31,035,000 |
| Net Income | $-113,137,000 | $-78,080,000 | $-40,037,000 | $-71,424,000 | $-32,220,000 |
| Net Margin | N/A | N/A | N/A | N/A | -3729.2% |
| EPS | $-0.61 | $-9.50 | $-0.22 | $-0.43 | $-3221645.62 |
Company Overview
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$35
Average Target
↑ 387.5% Upside
Now
$35
Low
$35
Average
$35
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 13th 2025 | Guggenheim | Initiation | Buy | $35 |
Earnings History & Surprises
CYBNBeat Rate
33%
Last 18 quarters
Avg Surprise
-150.0%
EPS vs Estimate
Beats / Misses
6/10
2 met exactly
Latest EPS
$-1.39
Q4 2025
EPS Surprise History
Q1 24
-133.3%
$-2.66vs$-1.14
Q1 24
No data
Q3 24
-1800.0%
$-0.38vs$-0.02
Q4 24
-452.6%
$-2.10vs$-0.38
Q1 25
+25.5%
$-0.38vs$-0.51
Q2 25
-100.0%
$-1.02vs$-0.51
Q3 25
-115.7%
$-1.10vs$-0.51
Q4 25
-87.8%
$-1.39vs$-0.74
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 9, 2026 | $-0.53 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.74 | $-1.39 | -87.8% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.51 | $-1.10 | -115.7% | ✗ MISS |
Q2 2025 | Jun 30, 2025 | $-0.51 | $-1.02 | -100.0% | ✗ MISS |
Q1 2025 | Feb 10, 2025 | $-0.51 | $-0.38 | +25.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.38 | $-2.10 | -452.6% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.02 | $-0.38 | -1800.0% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-0.12 | — | — |
Q1 2024 | Feb 14, 2024 | $-1.14 | $-2.66 | -133.3% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-1.90 | $-1.52 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.90 | $-1.90 | 0.0% | = MET |
Q2 2023 | Jun 27, 2023 | $-1.90 | $-1.90 | 0.0% | = MET |
Q1 2023 | Feb 14, 2023 | $-2.28 | $-1.52 | +33.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-2.28 | $-1.90 | +16.7% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-3.04 | $-2.28 | +25.0% | ✓ BEAT |
Q2 2022 | Jun 22, 2022 | $-2.66 | $-3.04 | -14.3% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-3.42 | $-3.04 | +11.1% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-2.66 | $-3.42 | -28.6% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-1.90 | $-2.66 | -40.0% | ✗ MISS |
Q2 2021 | Jun 28, 2021 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Latest News
Cybin To Voluntarily Transfer US Stock Listing From NYSE American To Nasdaq, Effective Jan. 5
➖ NeutralBenzinga•Dec 18, 2025, 12:35 PM
Guggenheim Maintains Buy on Cybin, Raises Price Target to $48
📈 PositiveBenzinga•Dec 3, 2025, 04:05 PM
Canaccord Genuity Maintains Buy on Cybin, Lowers Price Target to $45
➖ NeutralBenzinga•Nov 20, 2025, 04:02 PM•Also:
Cybin Q2 EPS $(1.39) Misses $(1.09) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 12:27 PM
Cybin Announces $175M Registered Direct Offering Of 22,277,750 Common Shares And Pre-Funded Warrants At $6.51/Share Or Warrant
➖ NeutralBenzinga•Oct 28, 2025, 12:02 PM
Psychedelic stocks gain after positive remarks from GOP Senator in North Carolina
📈 PositiveSeeking Alpha•Oct 14, 2025, 06:06 PM•Also: , ,
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
📈 PositiveBenzinga•Oct 13, 2025, 05:28 PM•Also: , ,
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
➖ NeutralBenzinga•Oct 2, 2025, 03:03 PM•Also: , ,
Cybin Highlights Neuropsychiatry Platform And Upcoming Clinical Milestones; Completes Enrollment Of 36 Participants In Phase 2 Study Of CYB004; Continues To Advance CYB003, The Company's Proprietary Deuterated Psilocin Analog, In Phase 3 Studies For The Adjunctive Treatment Of Major Depressive Disorder; Dosing Is Ongoing In The First Pivotal Study, APPROACH , With Expected Enrollment Of 220 Patients Across 45 U.S. Clinical Sites
📈 PositiveBenzinga•Sep 23, 2025, 09:16 PM
Cybin Cuts Size Of Mixed Shelf Offering To Up To $800M From Up To $1.0B
📉 NegativeBenzinga•Sep 17, 2025, 08:55 PM
'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
📈 PositiveBenzinga•Sep 12, 2025, 04:30 PM•Also: , ,
Cybin Completes Enrollment In Phase 2 Study Of CYB004 For Generalized Anxiety Disorder
📈 PositiveBenzinga•Sep 8, 2025, 11:32 AM
Cybin Names Co-Founder Eric So As Interim CEO As Doug Drysdale Steps Down
➖ NeutralBenzinga•Sep 2, 2025, 11:34 AM
'Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows' - Marijuana Moment
➖ NeutralBenzinga•Aug 28, 2025, 06:16 PM•Also: , ,
Cybin Announces Australian Approval For EMBRACE Phase 3 Study, Enrolling 330 Participants To Evaluate CYB003 In Major Depressive Disorder
📈 PositiveBenzinga•Aug 26, 2025, 11:37 AM
Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
📈 PositiveBenzinga•Aug 25, 2025, 06:53 PM•Also: , ,
'GOP Senator Is 'Confident' Psychedelics Access Will Expand Under Trump, Saying Many Veterans Speak To Him About The Benefits' - Marijuana Moment
📈 PositiveBenzinga•Aug 22, 2025, 07:53 PM•Also: , ,
'U.S. Senate Committee To Hold Hearing On Benefits Of Psychedelics For Military Veterans'- Marijuana Moment
📈 PositiveBenzinga•Aug 21, 2025, 06:35 PM•Also: , ,
Frequently Asked Questions about CYBN
What is CYBN's current stock price?
Cybin Inc. (CYBN) is currently trading at $7.18 per share. The stock has moved +6.06% today.
What is the analyst price target for CYBN?
No analyst price targets are currently available for this stock.
What sector is Cybin Inc. in?
Cybin Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is CYBN's market cap?
Cybin Inc. has a market capitalization of $0.36 billion, making it a small-cap company.
Does CYBN pay dividends?
No, Cybin Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
TNXP
Tonix Pharmaceuticals Holding Corp.
$17.09
Mkt Cap: $0.1B
Explore stocks similar to CYBN for comparison